How this company measures up on the fundamentals that matter
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Trading at $84, 16% above fair value of $73. Moderate competitive position. Passes all ethical screens. Ranks better than 96% of screened stocks.
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Trading characteristics and market positioning
Balance sheet strength and cash generation — the foundation of long-term value
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-27 | STARKS DANIEL J | Director | 10,000 | $926,537 | |
| 2026-04-24 | STRATTON JOHN G. | Director | 2,286 | — | |
| 2026-04-24 | CONROY KEVIN T | Director | 2,286 | — | |
| 2026-04-24 | MCKINSTRY NANCY | Director | 2,286 | — | |
| 2026-04-24 | KUMBIER MICHELLE A | Director | 2,286 | — | |
| 2026-04-24 | BABINEAUX CLAIRE FONTENOT | Director | 2,286 | — | |
| 2026-04-24 | MCDEW DARREN W | Director | 2,286 | — | |
| 2026-04-24 | GONZALEZ PATRICIA PAOLA | Director | 2,286 | — | |
| 2026-04-24 | AHUJA NITA M.D. | Director | 2,286 | — | |
| 2026-04-24 | O GRADY MICHAEL G | Director | 2,286 | — |
Congressional trading disclosures involving this instrument
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 27 May2026 | Josh Gottheimer | Democrat | sell | 1K–15K |
| 2026-04-13 | Ro Khanna | Democrat | Sale | 1K–15K |
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15